Stratifying body mass index categories by waist circumference thresholds improves mortality risk prediction in postmenopausal women.

While a healthy lifestyle naturally has important benefits, yet seeking weight loss alone might not give an adequate picture ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

A recent study finds that much of the cardiovascular disease seen in severely overweight people is driven by more than diabetes and high blood pressure.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

HealthDay News — The European Association for the Study of Obesity (EASO) framework may offer a more sensitive measure of obesity than traditional body mass index (BMI), according to a study published ...

• Future studies should report their results by age, gender, race/ethnicity; include the full data; include adverse events and other outcomes; control for both diet and physical activity in their ...

Rhythm Pharmaceuticals is advancing its oral obesity drug bivamelagon to Phase III studies after it significantly reduced body mass index (BMI) in all three doses.

Merck & Co. Inc. has strengthened its cardiopulmonary pipeline with its $10 billion acquisition of London-based-Verona Pharma plc. The deal brings Merck Ohtuvayre (ensifentrine) for chronic ...

Weight loss is known to improve health in obesity. A new study provides clues to how: by rejuvenating fat tissue and changing ...

Rhythm said results of the recent trial were also consistent with BMI reductions achieved with setmelanotide therapy in similar patient populations in past trials. Setmelanotide, an existing ...